Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorDe Filippis, Raffaele
dc.contributor.authorWolflein, Georg
dc.contributor.authorUm, In Hwa
dc.contributor.authorCaie, Peter David
dc.contributor.authorWarren, Sarah
dc.contributor.authorWhite, Andrew
dc.contributor.authorSuen, Elizabeth
dc.contributor.authorTo, Emily
dc.contributor.authorArandelovic, Oggie
dc.contributor.authorHarrison, David James
dc.date.accessioned2022-11-01T15:30:11Z
dc.date.available2022-11-01T15:30:11Z
dc.date.issued2022-11-01
dc.identifier281907553
dc.identifierc3be3f23-1554-46c2-a0dc-15d25fb309b5
dc.identifier85141816603
dc.identifier000880925200001
dc.identifier.citationDe Filippis , R , Wolflein , G , Um , I H , Caie , P D , Warren , S , White , A , Suen , E , To , E , Arandelovic , O & Harrison , D J 2022 , ' Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma ' , Cancers , vol. 14 , no. 21 , 5387 . https://doi.org/10.3390/cancers14215387en
dc.identifier.issn2072-6694
dc.identifier.otherORCID: /0000-0001-9041-9988/work/122215843
dc.identifier.otherORCID: /0000-0002-0031-9850/work/122216039
dc.identifier.otherORCID: /0000-0002-0407-7617/work/122216825
dc.identifier.otherORCID: /0000-0001-9999-4292/work/158122924
dc.identifier.urihttps://hdl.handle.net/10023/26287
dc.descriptionFunding: This work was supported by Medical Research Scotland (MRS), NHS Lothian, NanoStringTechnologies, and the Industrial Centre for AI Research in Digital Diagnostics (iCAIRD) which is funded by Innovate UK on behalf of UK Research and Innovation (UKRI) [project number: 104690].en
dc.description.abstractAlthough Immune Checkpoint Inhibitors (ICIs) have significantly improved the oncological outcomes, about one third of patients affected by Clear Cell Renal Cell Carcinoma (ccRCC) still experience recurrence. Current prognostic algorithms like the Leibovich Score (LS) rely on morphological features manually assessed by pathologists, and are therefore subject to bias. Moreover, these tools do not consider the heterogeneous molecular milieu present in the Tumour Microenvironment (TME), which may have prognostic value. We systematically developed a semi-automated method to investigate 62 markers and their combinations in 150 primary ccRCCs using multiplex Immunofluorescence (mIF), NanoString GeoMx® Digital Spatial Profiling (DSP) and Artificial Intelligence (AI)-assisted image analysis in order to find novel prognostic signatures and investigate their spatial relationship. We found that coexpression of Cancer Stem Cell (CSC) and Epithelial-to-Mesenchymal Transition (EMT) markers such as OCT4 and ZEB1 are indicative of poor outcome. OCT4 and the immune markers CD8, CD34 and CD163 significantly stratified patients at intermediate LS. Furthermore, augmenting the LS with OCT4 and CD34 improved patient stratification by outcome. Our results support the hypothesis that combining molecular markers has prognostic value and can be integrated with morphological features to improve risk stratification and personalised therapy. To conclude, GeoMx® DSP and AI image analysis are complementary tools providing high multiplexing capability required to investigate the TME of ccRCC, while reducing observer bias.
dc.format.extent20
dc.format.extent7365216
dc.language.isoeng
dc.relation.ispartofCancersen
dc.subjectMultiplexen
dc.subjectImmunofluorescenceen
dc.subjectNanostringen
dc.subjectImage analysisen
dc.subjectPathologyen
dc.subjectKidneyen
dc.subjectSpatial analysisen
dc.subjectQR180 Immunologyen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectNDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectMCCen
dc.subject.lccQR180en
dc.subject.lccRC0254en
dc.titleUse of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinomaen
dc.typeJournal articleen
dc.contributor.sponsorInnovate UKen
dc.contributor.institutionUniversity of St Andrews. Cellular Medicine Divisionen
dc.contributor.institutionUniversity of St Andrews. School of Computer Scienceen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews. Centre for Biophotonicsen
dc.identifier.doi10.3390/cancers14215387
dc.description.statusPeer revieweden
dc.identifier.urlhttps://www.mdpi.com/2072-6694/14/21/5387en
dc.identifier.grantnumberTS/S013121/1en


This item appears in the following Collection(s)

Show simple item record